Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outpatient dual-probe 24-hour pH-metry in extraesophageal reflux
2009-014539-20Phase 3Completed
- Sponsor
- University Hospital Ostrava
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lansoprazole in Extraesophageal reflux disease (LPR) and gastroesophageal reflux disease (GERD), sponsored by University Hospital Ostrava. Primary endpoint: Association of clinical severity with reflux episodes and PPI response. Started Jul 2009; status: completed.
02
Drugs
lansoprazole
03
Conditions
Extraesophageal reflux disease (LPR)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2009-014539-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014539-20.